首页 › 基金 › TOWERVIEW LLC › CRVS
TOWERVIEW LLC 对 CRVS 的持仓历史
CORVUS PHARMACEUTICALS INC · 医疗保健
TOWERVIEW LLC 在 Q3 2026 的 13F 申报中披露持有 CRVS(CORVUS PHARMACEUTICALS INC)70,000 股,市值约 US$806K,约占其申报组合的 0.59%,在其申报持仓中市值排名第 12 位。 TOWERVIEW LLC 最近 13 个申报季度中有 13 个季度披露了 CRVS 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
TOWERVIEW LLC 对 CRVS 的持仓演变
TOWERVIEW LLC 于 Q3 2023 首次披露 CRVS 持仓:342,478 股(约 US$500K)。 该持仓在 Q3 2025 达到峰值 170,000 股,市值约 US$1.3M。 在 13 次申报中,TOWERVIEW LLC 4 次增持、5 次减持、3 次保持不变。 最近一期申报(Q3 2026)显示持股 70,000 股、市值约 US$806K。 持仓曾出现大幅变动:Q3 2024 减持约 71% (随后一个季度股价上涨 1%)、Q1 2025 增持约 65% (随后一个季度股价上涨 26%)、Q1 2026 减持约 50% (随后一个季度股价上涨 2%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 342.48K | $500.02K | 新进 |
| Q4 2023 | 436.87K | $768.90K | 增持 |
| Q1 2024 | 382.50K | $680.85K | 减持 |
| Q2 2024 | 400.00K | $728.00K | 增持 |
| Q3 2024 | 117.50K | $620.40K | 减持 |
| Q4 2024 | 77.50K | $414.62K | 减持 |
| Q1 2025 | 127.50K | $405.45K | 增持 |
| Q2 2025 | 170.00K | $680.00K | 增持 |
| Q3 2025 | 170.00K | $1.25M | 持有 |
| Q4 2025 | 140.00K | $1.08M | 减持 |
| Q1 2026 | 70.00K | $1.02M | 减持 |
| Q2 2026 | 70.00K | $1.05M | 持有 |
| Q3 2026 | 70.00K | $806.40K | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CRVS 与 13F 数据
CRVS(CORVUS PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 67 只申报持有 CRVS,申报仓位最大的包括:ORBIMED ADVISORS LLC (US$107.0M), ADAMS STREET PARTNERS LLC (US$48.9M), PERCEPTIVE ADVISORS LLC (US$39.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CRVS 的基金
- ORBIMED ADVISORS LLC 7.17M 股 · $107.05M · Q2 2026
- ADAMS STREET PARTNERS LLC 3.28M 股 · $48.94M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.67M 股 · $39.85M · Q2 2026
- Deep Track Capital, LP 2.49M 股 · $37.23M · Q2 2026
- Vivo Capital, LLC 2.81M 股 · $32.32M · Q3 2026
- BRAIDWELL LP 2.13M 股 · $31.77M · Q2 2026
- Foresite Capital Management VI LLC 1.83M 股 · $27.36M · Q2 2026
- Boxer Capital Management, LLC 1.10M 股 · $16.43M · Q2 2026
- Catalio Capital Management, LP 1.08M 股 · $16.15M · Q2 2026
- Eversept Partners, LP 747.99K 股 · $11.18M · Q2 2026
- DCF Advisers, LLC 641.50K 股 · $7.39M · Q3 2026
- Nextech Invest Ltd. 450.00K 股 · $6.72M · Q2 2026
更多关于 TOWERVIEW LLC
常见问题
How long has TOWERVIEW LLC held CRVS?
TOWERVIEW LLC has disclosed CRVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is TOWERVIEW LLC's current position in CRVS?
As of Q3 2026, TOWERVIEW LLC holds 70.00K shares of CRVS (CORVUS PHARMACEUTICALS INC), valued at $806.40K, representing 0.59% of its reported portfolio and ranking #12.
Has TOWERVIEW LLC been buying or selling CRVS?
In the latest 13F filing (Q3 2026), TOWERVIEW LLC held unchanged its position in CRVS. The position peaked in Q3 2025 at 170.00K shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, PERCEPTIVE ADVISORS LLC, among 67 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.